Regulatory Profile for Glucose Self-monitoring Tools

Diabetes Self-Monitoring Devices in LMICs

Eudamed and CTIS: Lessons from EudraCT

Transparency and Medicines Policy in the EU

Missing clinical trial data in Europe

Statement to the 23rd WHO Expert Committee on the Selection and Use of Essential Medicines

Statement to WHA74 on GSPOA

Statement to WHA74 on Diabetes and Access to Insulin

HAI Statement on The Oslo Medicines Initiative at the WHO Virtual Consultation with Non-State Actors, 31 March 2021

Response to the Revision of the EU General Pharmaceuticals Legislation

Response to EU’s HERA Initiative Consultation

Transparency, Accountability and Access to Medicines: European Projects 2021

How the Netherlands and other EU Governments Respond to the Challenge of Sustainable Access to Medicines

Statement to EB148 on WHO reform: involvement of non-State actors in WHO’s governing bodies

Letter to Dr Tedros: Leadership and Advocacy for C-TAP

Statement to EB148 on expanding access to effective treatments for cancer and rare and orphan diseases, including medicines, vaccines, medical devices

Statement to EB148 on the COVID-19 response

Statement to EB148 on global strategy and plan of action on public health, innovation and intellectual property

Access to Internationally Controlled Essential Medicines in sub-Saharan Africa


Joint HTA Assessment in Europe: Progress in 2020

Cross-country Cooperation Schemes: A fair-weather solution to the issue of access to medicines in Europe?

FACT SHEET: Impact and Knowledge of COVID-19 and related measures in rural Kenyan households

Making Medicines Authorisation Procedures Work for Patients

Clinical Trial Transparency in the Netherlands: Mapping Unreported Drug Trials

European Commission Intellectual Property Action Plan

Partners for Change

SRHC: Availability, Affordability and Stock-outs – Uganda 2019

Driving Change in Access to Medicines – Annual Report 2019

COVID-19 Technology Access Pool

SRHC: Availability, Affordability and Stockouts – Zambia 2019